CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA‐DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million. CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), a first‐in‐class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been approved by the European Commission for treating adults with EPP.

Based in Melbourne, Australia, CLINUVEL has operations in Europe, the US and Singapore.

In 2010, CLINUVEL ventured into an area of dermatology where no other pharmaceutical company has yet succeeded, trialing a new drug, SCENESSE® (afamelanotide) in vitiligo as a combination therapy with narrowband ultraviolet B light therapy.

Winner of four Emmy® Awards, anchor and producer, entertainment reporter at WJBK Fox 2 Detroit, Mr Lee Thomas is a spokesperson for the US vitiligo community.

In this four part video series, shot in early 2012, he interrogated CLINUVEL’s CEO Dr Philippe Wolgen about SCENESSE® as a potential remedy in vitiligo.

CLINUVEL PHARMACEUTICALS sites use cookies to improve and personalise your experience. The sites may also include cookies from third parties. By using this site, you consent to the use of cookies. Learn More